{
    "title": "114_hr4641",
    "content": "Development of best practices for prescription opioids. The Secretary will convene a Pain Management Best Practices Inter-Agency Task Force with representatives from various departments to review and update best practices for pain management and prescribing medication. The Pain Management Best Practices Inter-Agency Task Force will include representatives from various departments such as the Department of Veterans Affairs, the Food and Drug Administration, the Department of Defense, the Drug Enforcement Administration, and others. It will also involve state medical boards, physicians, dentists, nonphysician prescribers, and hospitals. The Pain Management Best Practices Inter-Agency Task Force will also include pharmacists, first responders, experts in pain and addiction research, adolescent addiction research experts, representatives from pain management, mental health, addiction treatment, pain advocacy, veteran service organizations, and overdose reversal groups, as well as individuals in recovery from medication addiction. The Pain Management Best Practices Inter-Agency Task Force will include individuals with chronic pain, experts in military and minority health, and other relevant stakeholders. Members must be licensed in the state where they practice. The Pain Management Best Practices Inter-Agency Task Force will review and update best practices for pain management and prescribing medication within 180 days of being convened. This includes considering existing research and trends in areas with high rates of prescription opioid abuse and fatalities. The Pain Management Best Practices Inter-Agency Task Force will consider recommendations from conferences and guidelines, ongoing efforts at State and local levels, and medical organizations to develop improved pain management strategies, including opioid alternatives and monitoring programs to prevent medication diversion. The Pain Management Best Practices Inter-Agency Task Force will address the prevention of pain medication diversion, electronic prescribing of opioids, management of high-risk populations, and the unique needs of adolescents and young adults in pain management and substance use disorder treatment. The Pain Management Best Practices Inter-Agency Task Force will address various aspects including co-prescribing naloxone, research on substance use disorders among adolescents and young adults, and adolescent-specific treatment protocols. The curr_chunk discusses federal non-research programs and activities addressing prevention, treatment, and recovery from substance use disorders among adolescents and young adults, evaluating their effectiveness in prevention and treatment. The curr_chunk focuses on identifying gaps in federal efforts related to prevention, treatment, and recovery from substance use disorders among adolescents and young adults. It includes gaps in research, data collection, and measures to evaluate the effectiveness of these efforts. Public comments are solicited to amend best practices accordingly. The curr_chunk focuses on developing and disseminating best practices for pain management and prescribing pain medication, as well as identifying the need for new alternatives to opioids. The task force will review and update best practices for pain management and prescribing pain medication, considering existing efforts in the private sector, State, and local governments. The task force will not have rulemaking authority and must submit a report to Congress within 270 days, including a strategy for disseminating best practices. The task force will review and update best practices for pain management and prescribing pain medication, including a feasibility study on linking practices to registrations under the Controlled Substances Act, recommendations for improving prescribing practices at medical facilities, and the development of new alternatives to medication. The task force will review and update best practices for pain management, including exploring nonpharmacological and medical device alternatives to opioids. The House of Representatives passed the document on May 11, 2016. Karen L. Haas attested to it as the Clerk."
}